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HLA abnormalities on tumour cells for immune escape have been widely described. In addition, cellular
components of the tumour microenvironment, in particular myeloid derived suppressor cells (MDSC) and
alternatively activated M2 tumour-associated macrophages (TAMs), are involved in tumour promotion, progression,
angiogenesis and suppression of anti-tumour immunity. However, the role of HLA in these activities is poorly
understood. This review details MHC class I characteristics and describes MHC class I receptors functions. This
analysis established the basis for a reflection about the crosstalk among the tumour cells, the TAMs and the cells
mediating an immune response.
The tumour cells and TAMs exploit MHC class I molecules to modulate the surrounding immune cells. HLA A, B, C
and G molecules down-regulate the macrophage myeloid activation through the interaction with the inhibitory
LILRB receptors. HLA A, B, C are able to engage inhibitory KIR receptors negatively regulating the Natural Killer and
cytotoxic T lymphocytes function while HLA-G induces the secretion of pro-angiogenic cytokines and chemokine
thanks to an activator KIR receptor expressed by a minority of peripheral NK cells. The open conformer of classical
MHC-I is able to interact with LILRA receptors described as being associated to the Th2-type cytokine response,
triggering a condition for the M2 like TAM polarization. In addition, HLA-E antigens on the surface of the TAMs bind
the inhibitory receptor CD94/NKG2A expressed by a subset of NK cells and activated cytotoxic T lymphocytes
protecting from the cytolysis.
Furthermore MHC class II expression by antigen presenting cells is finely regulated by factors provided with
immunological capacities. Tumour-associated macrophages show an epigenetically controlled down-regulation of
the MHC class II expression induced by the decoy receptor DcR3, a member of the TNFR, which further enhances
the M2-like polarization. BAT3, a positive regulator of MHC class II expression in normal macrophages, seems to be
secreted by TAMs, consequently lacking its intracellular function, it looks like acting as an immunosuppressive
factor.
In conclusion HLA could cover a considerable role in tumour-development orchestrated by tumour-associated
macrophages.Introduction
Macrophages are tissue phagocytic cells that display the
main activity of clearance independently of immune
cells. However, they can be activated in response to either
innate or adaptive immune signals and they are able to
shape their phenotype to fit the microenvironment. In an
attempt to simplify their complexity, activated macro-
phages can be categorized into two distinct subtypes:* Correspondence: giuseppe.masucci@ki.se
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reproduction in any medium, provided the orclassically activated (M1) and alternatively activated (M2)
[1,2]. M1 macrophages are activated in the presence of
bacterial moieties (LPS) or Th1 cytokines (IFN-gamma).
In mice, M1-associated markers include interleukin-12
(IL-12), inducible nitric oxide synthase 2 (iNOS2) and a
high level of MHC class II molecules. Human macro-
phages do not show induction of iNOS2 under the same
conditions, despite having a similar phenotype. They have
an efficient antigen presentation capacity and, through
interaction with Th1 cells and NK cells, they are able
to kill pathogens and tumour cells. M1 macrophagesal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Marchesi et al. Journal of Translational Medicine 2013, 11:247 Page 2 of 15
http://www.translational-medicine.com/content/11/1/247antagonize tumourigenesis due to direct tumour-killing
mechanisms and amplification of Th1 responses, provid-
ing a positive feedback loop in the anti-tumour response
[1]. In contrast, M2 macrophages are activated in the pres-
ence of Th2 cells cytokines and basophil-secreted cyto-
kines (IL4, IL13, IL33) or induced by immune complexes
and TLR agonists as well as by IL-10 and glucocorticoids
[3-5]. The expression of resistin-like alpha (FIZZ1),
arginase-1, macrophage mannose receptor 1 and chitinase
3-like 3 identify mice M2 macrophages, while human M2
macrophages do not show induction of resistin-like-alpha,
arginase 1 and chitinase 3-like 3 but they up regulate
indoleamine 2,3-dioxygenase (IDO). Moreover, M2 mac-
rophages produce several growth factors (IL-10, EGF, FGF,
VEGF and TGF-beta) and they are also involved in para-
site clearance and allergy. M2 macrophages may enhance
tumour progression by releasing growth factors and prod-
ucts of the arginase-1/IDO pathway and by promoting
tumour angiogenesis [6].
Solid tumours are infiltrated by a heterogeneous immune
cell population, including different subsets of lymphoid and
myeloid cells [7]. The infiltration of tumour-associated
macrophages (TAMs) can represent an index of poor prog-
nosis in different types of cancer [8].
Mantovani and collaborators, as a result of a literature
review, suggest a switch of TAMs from M1-like to M2-
like phenotype as an adaptation to microenvironment
changes during tumour progression. In early carcinogen-
esis T cells drive M1-activated macrophages to eliminate
tumour cells except in advanced stages of tumour progres-
sion where microenviromental signals result in M2 polar-
ized TAMs that orchestrate smouldering, non-resolving
tumour promoting inflammation [9,10].
This fine property of TAMs to modulate their features
in relation to different microenviromental conditions is
clearly shown by Movahedi K. and co-authors [11]. Using
a mammary adenocarcinoma model, they provide a dy-
namic picture in which a subset of precursor monocytes
infiltrating the tumour gives rise to distinct TAM subsets.
These subsets are different at the molecular and functional
levels and were present in different intra-tumour microen-
vironments. TAMs with a high expression of MHC class
II and M1 markers are confined in normoxic tumour
areas, whereas M2-like TAMs with a low expression of
MHC class II and significantly higher proangiogenic activ-
ity are found in hypoxic tumour areas. Moreover, these
M2-like TAM subsets possess a poor antigen presenting
capacity and could suppress T-cell activation by using
different suppressive mechanisms such as: the secretion of
protease like Arg-1 [12], the releasing of immunosuppres-
sive cytokines like TGFbeta [8] and IL-10 [13] and of
chemokine-like CCL18 [14] the membrane expression
of B7-H1 [15] and BTN3A [16]. Importantly, the rela-
tive percentages of these distinct myeloid subpopulationsdramatically changed as tumours progressed: the TAM
subset expressing low MHC class II became gradually
the more represented population of the myeloid tumour
infiltrate [14].
The alterations of MHC class I molecules and cellular
components involved in the antigen processing and
presentation machinery have been widely described as
one of the main mechanism adopt by various type of
tumour cells to escape from the immune system. The
frequency of the HLA class I abnormalities is highly
variable in many solid and hematopoietic tumours.
These deviations include the complete absence or
down-regulation of HLA class I expression or of HLA
class I allo-specificities in frequent association to an im-
pairment of a single or various members of the antigen
processing and presenting machinery. In most cases, it
seems that the HLA class I abnormalities result from a
deregulation rather than a structural defect suggesting
an intervention at the epigenetic, transcriptional and or
posttranscriptional level [17]. This observation increase
even more the importance of studying the crosstalk
between the tumour cells and the microenvironment.
This review tries to provide a snapshot of the complex
and dynamic scene of cancer HLA is the focus, but the
subject matter has been broadened to include the tumour
cells, the microenvironment and their interaction.
Classical and non-classical MHC class I
HLA-A, -B, -C
HLA-A and HLA-B antigens are constitutively expressed
on macrophages and are not altered during macrophage
differentiation [18], whereas HLA-C antigens are consti-
tutively expressed at much lower levels. The reason for
this is based on the necessity of maintaining the NK cell
activation at a threshold that assures immunological
surveillance. The regulation of HLA-C expression occurs
at different steps of the biosynthesis pathway [19,20].
The cytoplasmic tail of HLA-C contains internalization
and lysosomal targeting signals that could be inhibited
upon macrophage differentiation [18]. The consequences
are that undifferentiated primary monocytes, similarly to
other cell types, express low levels of HLA-C, while
differentiated macrophages show an up-regulation of
HLA-C expression.
The MHC class I complex can spontaneously dissoci-
ate and be released as Beta2-microglobulin free form by
activated T lymphocytes [21], or can escape from the ER
as free heavy chain Beta2-microglobulin and appears as
a beta2-microglobulin-free form on the tumour cell
surface [22].
Consequently, MHC class I molecules are present on
the cell surface in two forms: one is the Beta2-
microglobulin-associated form and the other is a free
heavy chain (HC) with an open conformation. The
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surface can be modified by the activation state or by
transformation [21]. The free HC of HLA-C molecules
are commonly observed on normal cells like activated
lymphocytes [23] and are stably expressed by melanoma
cell lines [22].
Thus, HLA-C is characterized by a low affinity for
Beta2-microglobulin and, therefore, it might be signifi-
cantly expressed on the cell surface in the free heavy-chain
form of activated macrophages [18]. The hypothetical role
of HLA-C, both the B2-microglobulin associated form and
the free HC form has still to be explored.
HLA-G
HLA-G consists of seven isoforms (four membrane-
bound: from HLA-G1 to HLA-G4 and three soluble: from
HLA-G5 to G7) that are generated by alternate splicing.
In addition, soluble HLA-G could be shed by the proteo-
lytic cleavage of membrane bound isoforms. The isoforms
mainly described, the cell-surface HLA-G1 and the soluble
form HLA-G5, are detected as Beta2-microglobulin-free
heavy chains and as disulphide-bound homodimers and
homotrimers [24,25]. Zilberman et al. identify both surface
and soluble HLA-G5 dimers in tumour cells and malig-
nant ascites [26].
Multimeric MHC class I molecules in most cases are
able to induce a more potent immune response in com-
parison with monomers [27]. In fact, dimers of HLA-G1
and HLA-G oligomers bind with increased affinity the
inhibitory receptors of the leukocyte immunoglobulin-
like family (ILT2 and ILT4) than monomers, resulting in
an enhanced inhibitory function of myeloid cells in vitro
[25,28,29] and in vivo [30,31].
The different isoforms of HLA-G have been shown to
be expressed both by the tumour cell and by tumour
associated macrophages/monocytes in lung cancer, mel-
anoma, breast cancer and neuroblastoma [32-35] and by
glioblastoma infiltrating microglia [36]. In addition, soluble
HLA-G can be secreted in the peripheral blood of cancer
patients [37-44]. An interesting study shows that soluble
factors released by neuroblastoma cells could reach the
blood stream and induce a programme of “frustrated acti-
vation” with features of macrophage-like activated cells in
systemic monocytes. Thus, the release of higher amounts
of immune-suppressive soluble HLA-G and less IL12 indi-
cates a shift towards a more anergic phenotype [45].
HLA-E
HLA-E surface expression requires the expression of
certain MHC class I molecules including HLA-A, HLA-B,
HLA-C, and HLA-G (not HLA-F), which possess a
nonameric peptide in their leader sequence capable of
binding to HLA-E. This is usually co-expressed in HLA-G
positive tissue [46,47]. HLA-E cell surface expression islimited to extra villous trophoblast cells, endothelial cells
of all types of vessels, B- and T lymphocytes, NK cells,
monocytes and macrophages [48].
Moreover, HLA-E is expressed by tumour cells of the
following cancers: colorectal, laryngeal, ovarian, breast,
melanoma, lymphoma and glioma [49-56]. The observed
association of antigen processing defects, down-regulation
of Beta2-microglobulin or other MHC I heavy chain genes
and induction of HLA-E in malignant tissues suggests that
HLA-E expression becomes independent by the action of
the nonameric peptides expression [57]. The nonameric
peptides are replaced by peptides derived from self-
proteins [58] that confer invisibility by NK lysis [59].
HLA-E could be released in soluble forms by melanoma
cells [54,60]. Kren L. et al. detected HLA-E expression on
tumour infiltrating microglia/macrophages in most cases
of glioblastomas analysed, while HLA-E expression is lack-
ing in normal microglia [36]. Since most tumour infiltrat-
ing microglia/macrophages are found at the border of the
ischaemic area, hypoxic stimuli enhance the expression of
the HLA-E and HLA-G-immune modulatory molecule
[61] as far as it induces M2 polarization [11].
HLA-F
HLA-F is the least characterized member of the non-
classical HLA class I molecules. It is intracellularly
retained by almost all resting leukocytes, except B
lymphoblastoid- and monocytic cell lines which express
it on the cell membrane [62] but it may reach the cell
surface under activation. HLA-F is not up-regulated in
CD4+, CD25+ FoxP3+ regulatory T cells when they are
activated, whereas, under identical conditions, CD4+,
CD25- T cells show strong surface HLA-F expression.
HLA-F could provide a signal that indicates an activated
immune response to regulatory T cells and it could
trigger the secretion of immunosuppressive cytokine
leading to tolerance [63]. HLA-F is suggested as an
unfavourable prognostic factor in patients affected by
NSLC [64] and by oesophageal squamous cell carcinoma
[65]. In addition, anti-HLA-F IgG is present in the sera
derived from various types of cancer patients, but not in
the sera derived from healthy donors [66].
HLA-F expression is entirely dependent on its cytoplas-
mic tail to exit from the endoplasmic reticulum. Although
it is not known if this pathway requires peptide binding, it
is conceivable that export of HLA-F from ER may be a
peptide independent pathway [67] even though HLA-F
can bind to TAP molecules [68]. Consequently, it is
expressed both as a Beta2-microglobulin-free HC form
independently from TAP and as a heterodimer form with
Beta2-microglobulin [62]. HLA-F surface expression is
strictly dependent on the expression of MHC class I HC
as far as it is downregulated upon perturbation of the
same molecule. Moreover, MHC class I is able to interact
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conformer free of peptides. All these data suggest that the
physical cis-interaction plays a role in the function of
MHC class I molecule in activated immune cells [69].
The surface plasmon resonance studies show that
tetrameric complexes of HLA-F are able to interact with
affinity to the inhibitory receptors of the leukocyte
immunoglobulin-like family ILT2 and ILT4 [70]. The
emerging questions are, what are the roles of HLA-F on
TAMs and of its interaction with MHCclass I molecules
and with the receptors ILT2 and ILT4? The structure of
classical and non classical MHC class I molecules is
simplified in the Table 1.
MHC class I receptors
Leukocyte immunoglobulin-like receptors
Leukocyte immunoglobulin-like receptors (LILRs) are
HLA receptors widely expressed by myeloid cells and
their role as modulators of macrophage activation has
been well described [71,72]. Their importance in tumour
immune escape can be foreseen by the observation thatTable 1 Summary of structure of MHC class I molecules and t
MHC class I CELL TYPE B
f
HLA A, B Nearly all cells +
Tumor cells +
TAMs ?
HLA C Nearly all cells +
Activated immune cells +
Tumor cells (melanoma) +
TAMs ?
HLA G Fetal derived placental cells +




HLA E Extravillous trophoblast cells +
d




HLA F Resting immune cells -
Activated immune cells +
Tumor cells (NSLC and esophageal carcinoma) +
TAMs ?LILRs are exploited by viruses to evade from the immune
system. A clear example is shown by a study conducted
on HIV variant showing that a mutated immunodominant
virus epitope linked to HLA-B2705 creates a better ligand
for ILT4 on myelomonocytic cells and this interaction
leads the antigen presenting cells (APCs) to a tolerogenic
profile [73]. In a similar manner, CMV encodes epitopes
which, linked to MHC class I molecules, is able to increase
affinity to ILT2 compared with regular MHC class I mole-
cules reducing antiviral immune surveillance [74].
The LILR family includes inhibitory (LILRB) and activat-
ing (LILRA) receptors. The best-characterized LILR mem-
bers remain the inhibitory receptors LILRB1 (ILT2) and
LILRB2 (ILT4). ILT2 is widely expressed on myeloid and
lymphoid cells, while ILT4 is almost exclusively expressed
on monocytes, macrophages and dendritic cells. ILT2 and
ILT4 bind in trans with a broad specificity [75] both
classical and non-classical HLA class I molecules. These
recognize the non-classical HLA-G with a higher affinity
[76,77]. Moreover, ILT2 cannot recognize the Beta2-free
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like HLA-B27 [78], HLA-C [79] as well as the non-
classical Beta2-microglobulin-free HLA-G molecules [77].
This in trans interaction has a different affinity between
the soluble forms of ILT2 and ILT4 and several MHC class
I molecules [80]. Jones et al. studied LILRs binding to the
products of >90 different HLA class I alleles [79]. ILT2
and ILT4 were linked to different HLA alleles with
different strength in relation to amino acid motifs
within the alpha3 region (polimorphisms) and HLA I
class conformation. The ligation of individual HLA class
I alleles to ILT2 and ILT4 may alter the signalling
through the inhibitory receptor and consequently the
level of activation of APCs. Actually, HLA allele B*3503
binds ILT4 significantly stronger than other HLA class I
molecules do, independently of the presented epitopes
[81]. Consequently, HIV-1-infected, HLA B*3503 carriers
have APCs with poor functional properties and an acceler-
ated HIV-1 disease.
Among activating receptors, LILRA1 marks mono-
cytes, LILRA2 is expressed on monocytes, macrophages,
neutrophils, eosinophils and basophils [82]. LILRA3 is a
homologue of LILRA1 but lacks the transmembrane
domain and is therefore a secreted molecule, mainly
produced by macrophages [83]. These recognize MHC
class I molecules [75]. On the other hand, LILRA1 and
LILRA3 display a preference for specific alleles Beta2-
microglobulin-free forms [79], most of which belong to
the HLA-C locus [84].
While the affinity of ILT4 for free heavy chains of dif-
ferent MHC class I antigens results in a slightly reduced
than completed MHC-I form, LILRA1 and LILRA3 only
recognize open conformer, classical and non-classical
HLA class I antigens, especially HLA-C alleles [79,85].
LILRA1 binding to HLA-B27 has also been reported
[78]. Another strong ligand for LILRA1 and LILRA3 is
the free form of HLA-B*0801 [79], a component of the
MHC 8.1 ancestral haplotype associated with autoimmune
conditions mainly due to an exaggerated Th2-type cyto-
kine response [84]. This haplotype is also predictive of a
shorter progression free and overall survival in non-
Hodgkin lymphoma [86] and in malignant melanoma [87].
We can suppose that macrophages dipped in tumour
microenvironment and pushed by Th2-type cytokines,
due to the interaction between LILRA and the complex
ancestral haplotype-cancer antigen-differentiate in M2-
like macrophages. Hence, this could explain how MHC
8.1 haplotype could work as a prognostic factor in patients
affected by NHL and melanoma.
LILRA2 does not bind to MHC and the reason is linked
to its extracellular domain, which reveals structural shifts
of the corresponding MHC-binding amino acid residues
in comparison with ILT2 or ILT4 [88]. This explains the
lack of binding to MHC molecules. Moreover, it seemsthat LILRA2 forms a domain-swapped dimer. The
structure described supports the dimer conformation in
solution observed earlier, and implies a stress-induced
regulation by dimerization. Thus, its stimulation, simi-
lar to LILRA1, induces the shift from a Th1 production
(IL12) towards Th2 profile (IL-10). This is supported by
an activating mutation located in the linker region of
the receptor, responsible for a risk for some auto-
immune diseases such as systemic lupus erythematosus
and microscopic polyangiitis [82]. LILRA2 might be an
immune modulator either by inhibiting DC differentiation
or by stimulating an alternative macrophage differenti-
ation pathway leading to a reduced antigen presenting
capacity [89]. A role of LILRA receptors in TAMs could
be postulated, but it has not yet been shown.
Moreover, the Beta2-microglobulin-free MHC I class
molecules are able to cis-associate with LILR members
modulating the receptor-mediated internalization and
the signalling. The function of this interaction seems to
be related to the ability of working as regulators of in
trans ligand-receptor interactions amplifying or dampen-
ing the efficiency of the signalling [90]. The cis-interaction
between MHC I class and ILT2 is well established in mast
cells dampening cell activation [91]. No information is
available on the role in TAMs.
Killer cell immunoglobulin-like receptor (KIR)
The Killer cell immunoglobulin-like receptor (KIR) family
regulates the activation state of NK cells upon recognition
of MHC class I ligands on the surface of target cells
[92-94]. The inhibitor-receptors are expressed on the cell
surface including KIR2DL1/2/3 and KIR3DL1/2. The first
group recognizes HLA-C and the second group HLA-A
and HLA-B. The activator receptor is KIR2DL4, which re-
sides in the endosome. The only known ligand is HLA-G.
Both soluble HLA-G5 and HLA-G, shed from the cell sur-
face of transfected cells, are accumulated into endosomes
that contain KIR2DL4 [95]. It is likely that the transient
passage of KIR2DL4 at the cell surface, either by newly
synthesized KIR2DL4 or by the recycling of endosomal
KIR2DL4, is sufficient to capture soluble HLA-G and
transport it to endosomes [96]. Analysis of the transcrip-
tional response to activation via KIR2DL4 revealed the up-
regulation of a restricted set of chemokines and cytokines,
including IFN-gamma, TNFalfa, IL1Beta, IL6 and IL8
that can promote vascular remodelling either directly or
indirectly by acting on other cell types in the local
microenvironment [95,97,98].
The complex nonameric peptide-HLA-E links the
heterodimer CD94/NKG2 receptor expressed by approxi-
mately 50% of NK and activated cytotoxic T lymphocytes
[99]. The NKG2 family includes activating members like
NKG2C and NKG2E and an inhibitory member NKG2A
[100]. The complex nonameric peptide HLA-E binds the
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than the other receptors. This determines the protection
from HLA-E positive cells from NK and CTL dependent
lysis [101,102].
A comprehensive summary of MHC class I antigens,
their receptors and function is shown in Tables 1, 2 and 3.
MHC class II molecules
MHC class II gene expression is exclusively governed by
the master regulatory factor CIITA (class II transactivator)
[103]. The MHC class II expression in TAMs is repressed
by the soluble member of the TNF receptor super family,
decoy receptor 3 (DcR3), through the histone deacetylation
of the CIITA promoter [104]. Chang et al. propose a
more complex role of DcR3 as a modulator of macro-
phage differentiation and as a promoter of alternatively
activated macrophage polarization up-regulating genes
characteristically expressed in M2 macrophages, while
down-regulated genes identify M1 macrophages. Coher-
ently in DcR3 transgenic mice, the Th1 cell-response is
attenuated and deviates towards the Th2 phenotype
[105] and Th2 derived cytokines skew M2-like macro-
phage polarization.
DcR3 is a novel immune-suppressive factor up-
regulated and secreted by tumour cells like lymphoma
[106], glioma [107], lung and colon cancer [108],
gastrointestinal tract cancer [109], and kidney cancer
[110]. It is able to down-regulate the activation of DC
[111] and macrophages [112], and to induce dendritic
cell apoptosis [113].
DcR3 is able to promote tumour development in vivo
through the regulation of TAM differentiation [114]. In
fact, when DcR3 is regulated by the CD68 promoter in
transgenic mice, the tumour grows faster and metastasisTable 2 Summary of MHC class I molecules expressed/release
and the function of their interaction
MHC (tumor cells) RECEPTOR (myeloid cells) FUNCTION
Membrane HLA-G1 and
soluble HLA-G5




Membrane HLA-A-B-C ILT2 and ILT4 on
macrophages/TAMs
- Turning-dow
LILRA1 and LILRA3 on
macrophages/TAMs
- Stimulation o




ILT2 on MDSC -Expansion of
-Secretion of T
macrophage d
ILT4 on monocytes - Inhibition of
- Developmen
MHC class I molecules can be used by tumor cells: to modify the function of macro
maturation and to expand MDSCs which, secreting Th2 cytokines, contribute to M2is more common than in wild type mice. Moreover, the
tumour bulk has a more elevated infiltration of DcR3-
overexpressing TAMs (characterized by up-regulation
of arginase activity and down-regulation of MHC class
II expression). Interestingly, treatment with a histone
deacetylase inhibitor can restore MHC class II expres-
sion in TAMs in vitro [112] and inhibit tumour growth
in the transgenic model [114]. This may be of interest
for future cancer immunotherapy strategies.
BAT3 is the product of a group of genes adjacent to
the HLA-B locus, designated as B-associated transcripts
(BATs). Kamper et al. [115] described that BAT3 regu-
lates HLA class II expression and investigated the mode
of BAT3 action on HLA class II genes. IFN-gamma,
(key cytokine inducting Th1 response and M1 classical
macrophage activation) modulates the expression of
CIITA and strongly elevates BAT3 transcription in
various tumour cell lines and in primary macrophages.
Following IFN-gamma treatment, BAT3 chaperones
CIITA and the complex translocates into the nuclear,
where CIITA binds to the enhanceosome of HLA class II
promoters enhancing HLA II gene transcription. Thus,
BAT3 is critical to maintain HLA class II expression during
the cell-mediated immune response. Coherently, in vitro
exposure to INF-gamma could “re-educate” TAMs towards
M1-polarized immune-stimulatory macrophages [116].
BAT3 has different intracellular roles as a chaperone: it
monitors protein quality and refolding [117] and in
complex with E1A-binding protein p300, BAT3 is
required for the p53 acetylation in response to DNA
damage resulting in DNA repair or in cell apoptosis
[118]. BAT3 could be released as a BAT3 surface-positive
exosome by accessory cells or tumour line cells in re-
sponse to stress signals and engage NKp30, a receptord on/by tumor cells, the related ligands on myeloid cells
References
of LILRB receptor on macrophages/TAMs - LeMaoult J., 2005 [130]
n macrophage activation level - Jones D.C., 2011 [79]
n macrophage activation level - Jones D.C., 2011 [79]
f the alternative macrophage differentation - Lee D.J., 2007 [89]
TGFbeta1 resulting in blood monocytes
d suppression of their cytotoxic function
- McIntire R.H., 2004 [122]
- Ashcroft G.S., 1999 [123]
MDSC with enhanced suppressive activity - Zhang W., 2008 [124]
h2 cytokines able to skew the alternative
ifferentation
- Agaugue S., 2011 [125]
maturation of monocyte-derived APC - Ristich V., 2005 [129]
t of tolerogenic APC
phages promoting their differentation into TAMs, to interfere with monocytes
polarization of macrophages.
Table 3 Summary of MHC class I molecules expressed/secreted on/by macrophages/tumor associated macrophages,








ILT2 on NK cells - Negative regulation of INFgamma secretion - Morel E. 2008 [133]
ILT2 on T cells - Negative regulation of T cell function - Dietrich J. 2001 [136]
Membrane HLA-A-B KIR3DL1/2 on NK cells
and effector T cells
- Inhibition of cytolitic function - Anfossi N. 2004 [93]
- Long E.O. 2008 [94]
Membrane HLA-C KIR2DL1/2/3 on NK cells
and effector T cell
- Inhibition of cytolitic function - Colonna M. 1993 [92]
- Falk C.S. 1995 [132]
Membrane HLA-G1 - HLA-G1 is acquired through trogocytosis by CD4+ and CD8+ T
cells resulting their temporarily reversion to regulatory T cells
- LeMaoult J. 2007 [143]
Soluble HLA-G5 ILT2 and ILT4 on myeloid
APC
- secretion of the cytokine TGF-beta1 that contributes to T cells
peripheral tolerance
- McIntire R.H. 2004 [122]
- Turning down myeloid APC activation level - Jones D.C. 2011 [79]
KIR2DL4 on CD56bright
NK cells
- Secretion of pro-angiogenic cytokines and chemokines - Rajagopalan S. 1999 [147]
- Rajagopalan S. 2012 [96]
CD8 on activated CD8+ T
cells and CD8+ NK cells
- Fas/Fas ligand mediated cell death - Contini P. 2003 [145]
- Puppo F. 2002 [146]
- LeMaoult J. 2004 [144]
Membrane HLA-E CD94/NKG2A on NK cells
and cytotoxic T cells
- Production of immune-suppressive cytokines (IL-10 and TGF-beta1)
by NK cells
- Jinushi M. 2004 [148]
- Inhibition of cytolitic function - Braud V.M. 1998 [46]
- Borrego F. 1998 [102]
MHC class I molecules can be used by TAMs to promote tumor angiogenesis and to dampen immune response against tumor cells both directly inhibiting NK
and T cells function and indirectly inducing the secretion of immunosuppressive cytokines.
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NK activation and killing of accessory or tumour cells and
tumour rejection in a multiple myeloma xenograft model.
It is likely that other immune-suppressive factors, such as
the soluble BAT3 form (purified supernatant and derived
from tumour cell culture in response to non-lethal heat
shock) act in a suppressive manner inhibiting NK cell-
dependent cytokine release. So far, the existence of a
different isoform of BAT3 that could be released in an
exosomal or soluble form with a NK activatory or
inhibitory function cannot be ruled out. BAT3 could be
considered a sensor for DNA instability or damage
through its links to p53 function, able to alert the
immune system via an activating receptor on NK cells.
At the same time, BAT3 is a cross talk mediator
between NK and accessory cells.
In consideration of the important intracellular and
immunological functions, BAT3 could have a crucial role
in tumour promotion. This is corroborated by a linkage
disequilibrium study suggesting BAT3 as a strong candi-
date for lung cancer susceptibility [121].
Final reflections
As macrophages come into close association with tumour
cells, they are exposed to high concentrations of solubleHLA-G. The binding of HLA-G5 to inhibitory receptors
ILT2 and ILT4 stimulates macrophage production of
TGF-beta1 [122] resulting in a further recruitment of
monocytes from blood circulation and suppression of their
cytotoxic function [123].
In ILT2 transgenic mice, HLA-G engagement of ILT2
receptors results in expansion of the population of mye-
loid derived suppressor cells (MDSC) with an enhanced
suppressive activity. Moreover, ILT2 engagement results
in increased production of IL-4 and IL-13, which are
directly involved in the up-regulation of Arginase 1, a
well-known marker of M2 macrophage polarization
[124]. ILT2 ligation induces Th2 cytokine production by
MDSC, which, in turn, influences M2 like-macrophage
differentiation and stimulates the expansion of the
immune-suppressive population. A recent paper shows
for the first time that in vivo HLA-G skews the cytokine
balance in favour of Th2 and stimulates expansion of
MDSCs [125].
The interaction between HLA-G and monocytes due to
ILT4 [126,127] inhibits maturation of human monocyte-
derived APCs resulting in a reduced expression of MHC
class II antigens and co-stimulatory molecules through
Stat3 activation [128]. A study using human monocyte-
derived DCs and LILRB inhibitory ILT4-transgenic mice
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genic APCs with arrest maturation/activation of myeloid
DCs and the gene expression profile provides evidence
that HLA-G induces tolerogenic DCs by disruption of
the MHC class II presentation pathway [129].
Moreover, HLA-G1 and HLA-G5 interacting in trans
with ILT2 and ILT4 on the membrane surface of mac-
rophages induces up-regulation of the same inhibitory
receptors in circulating/infiltrating macrophages even
in the absence of an on-going immune response. The
HLA-G-dependent up-regulation of HLA-G receptors
might increase the activation threshold of the macro-
phages thus limiting the capabilities of the immune
system to initiate a response against HLA-G expressing
tissues. Furthermore, it induces the sensitivity of mac-















Figure 1 Tumour cells express classical and non classical MHC class I.
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with KIR receptors.
The classic MHC class I (HLA A and HLA B) can
interact, with varying degrees of strength, with ILT2
and ILT4 on the meanwhile recruited myeloid cells in
relation to the HLA I polymorphisms and HLA I class
conformation negatively conditioning the level of mye-
loid activation. The Beta2-microglobulin-free forms of
HLA-C molecules can engage ILT4 turning down the
macrophages activation level as well as LILRA1 and
LILRA3 on the same cells pushing the M2 alternative
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population.
TAM surface expression of HLA-C molecules, even in
the absence of peptide, could be sufficient to inhibit HLA-
C specific NK cells [92,131] and non-MHC-restricted
effector T cells [132] due to KIR2DL1/2/3.
Furthermore, HLA I class I molecules expressed on
APCs negatively regulates NK-derived IFN-gamma se-
cretion through the inhibitory receptor ILT2 [133]. Thus
NK-derived IFN-gamma has a key role in polarization
toward Th1 immune response [134] and it is critical
for the induction of a tumour-specific cytotoxic T cell
response [135].
Dietrich et al. show that ILT2 and TCR co-localize at
the immunological synapse formed between T cells and













Figure 2 TAMs express classical and non classical MHC class I. The cla
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function as an inhibitory co-receptor, first blocking bind-
ing of CD8 and second by bridging ILT2 into proximity
with the TCR engaging the same peptide MHC-I [136].
However, there also exist other processes to inhibit T
cell response: ILT2 could be efficiently transferred from
monocytes to autologous T cells by trogocytosis and in-
tegrate within the plasma membrane of the acquirer T
cells. Furthermore, the acquired receptors can access
compatible signalling machinery within acquirer T cells
and use it to signal and alter the functions of their new
host cells [137].
The soluble HLA-G secreted or shed by TAMs mediates
tolerance due to the induction of immune-suppressive
T cells [138] through the engagement of the LILRB in-
hibitory receptors ILT2 and ILT4 on myeloid APCs [138]-secretion of pro-angiogenic 
cytokines
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beta1 by myelomonocytic cells [122]. TGFbeta1 is
known to contribute to tolerance in peripheral lym-
phocytes [139].
HLA-G1 can be also acquired through membrane
transfer or trogocytosis by CD4-positive T cells and
CD8-positive T cells from APCs, like macrophages
during the process of immunological synapse formation
between TCR and MHC class II or I and or CD28 and
B7 [140,141,142]. HLA-G trogocytosis depends on
the activation status of the acquirer cells and, once acti-
vated, T cells efficiently capture APC-produced molecules
regardless of their antigen specificity. T cells reverse tem-
porarily their function from effectors to regulatory cells
inhibiting T-proliferative responses or exhibit an enhanced
suppression activity. This “emergency” suppression mech-








Figure 3 Regulation of MHC class II expression on TAMs. The tumour ce
class II expression and a promoter of M2-like macrophage polarization (TAM p
expression on normal macrophages during the cell-mediated immune respon
factor which inhibits NK cell-dependentcytokine secretion.borrowed HLA-G1 at the cell surface. However, it might
also be sufficient to delay immune reactions and give time
for real regulatory cells to differentiate and take over
[143]. Furthermore, HLA G1 transfected APC lines func-
tion as immune-inhibitory cells capable of turning off
alloproliferative responses of PBMCs as well as purified
CD4+ T cells and of inducing a long term antigen-specific
unresponsiveness, thus promoting a long lasting immune
ignorance/tolerance [144].
HLA-G1 can be shed as soluble HLA-G by HLA G1
transfected APC lines in the microenvironment inducing
the apoptosis of activated CD8+ T cells and NK [144],
through CD8 ligation [145] or by enhancing the Fas
ligand expression on cytotoxic effectors and triggering
Fas/Fas ligand mediated cell death [146]. It is note-
worthy that HLA-G in contrast to other MHC class I
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tor results in the activation of NK cells, not for cytotox-
icity, but for cytokine and chemokine secretion with a
pro-angiogenic purpose [96].
Moreover, TAMs could express non-classical HLA class
I molecules such as HLA-E. CD94/NKG2A heterodimers
constitute NK cell inhibitory receptors that recognize
the molecule HLA-E. Their interaction results in the
production of the immune-suppressive cytokines IL-10
and TGF-beta by NK cells [148] as well as in the protec-
tion of HLA-E expressing cells by NK and CTL-
dependent lysis [101,102].Conclusion
In conclusion, as summarized in Figures 1 and 2, both
classical and non-classical MHC class I molecules
expressed by tumour cells and TAMs might serve as im-
portant moderators of immune response attendees and
the balance between the expression of MHC I molecules
as free HC or as conformed proteins would determine
the strength of such an immune response.
Indeed this review casts light on inhibitory and activatory
LILRs as novel potential trigger factors of the tolerogenic
profile and of M2-like alternative polarization on TAMs
in response to the interaction with the classical and non
classical MHC class I.
Other interesting potential targets of treatment repre-
sented in Figure 3, are DcR3 and BAT3.
The tumour cells can release DcR3 in the microenviron-
ment, which not only decreases the MHC class II expres-
sion on macrophages, but also alternatively promotes their
M2 polarization.
BAT3 is a critical factor for maintaining MHC class II
expression on macrophage cell surfaces when acting on
intracellular sites. However, when cancer and accessory
cells, like TAMs, secrete BAT3 in the tumour micro-
environment, this looks like acting as an immune sup-
pressor factor.
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